NXL
Nexalin Technology, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$4.75
−6.85%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.95
From 52W high−56.62%
Volume14837.00
Market cap$4.06M
P/E (TTM)—
P/S (TTM)18.7x
Div yield—
Key dataSep 18, 2026
Open
$4.95
From 52W high
−56.62%
Volume
14837.00
Market cap
$4.06M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
37.1
MomentumView details →
1D Return
−6.85%
YTD Return
+792.47%
SummaryUpdated Jun 1, 2026
Nexalin Technology, Inc. (NASDAQ:NXL) is a medical device company founded in 2021 and headquartered in Houston, Texas. The company went public in September 2022 and specializes in developing neurostimulation products for treating mental health conditions. Nexalin focuses on non-invasive, drug-free therapeutic devices that use proprietary frequency-based waveforms to stimulate brain structures associated with various mental health disorders.
Similar companies
Latest newsMore news →
Carolyn Shelton departed as Senior Vice President of Quality, Regulatory, and Clinical Affairs at Nexalin Technology, Inc., effective August 28, 2026, with severance including one month of base salary, a $20,000 bonus for 2026, accelerated stock option vesting, and health insurance subsidy through September 30, 2026.18d agoNexalin Technology, Inc. received a notice from Nasdaq on 2026-08-14 for non-compliance with the Stockholders' Equity Requirement (Rule 5550(b)(1)) and requested a hearing before the Nasdaq Hearing Panel to present its remediation plan.34d ago